The aim of the research was to assess the effectiveness of Antral regarding the impact on the intensity of lipid peroxidation, antioxidant system factors in NASH patients against the background of obesity and comorbidity with COPD.
Material and methods of research: 76 NASH patients with class I obesity of and COPD 2-3 D were examined: 23 patients (group 1 – control group) received basic NASH therapy (Esentsiale forte N (Sanofi Avensis/Gutterman and Cie GmbH) 300 mg, 2 caps., 3 times per day) for 30 days and COPD therapy (Symbicort Turbuhaler (budesonide 160 mg/d + formoterol fumarate 4,5 mg/s) (AstraZeneca AB, Sweden) inhaled 2 times per day for 30 days, Berodual (ipratropium/fenoterol (250/500 mg/ml) (Institute de Angele Italy/Boehringer Ingelheim International GmbH) nebulizer inhalation 2 times per day, azithromycin (Azithro Sandoz, Ukraine Sandoz) 500 mg, 1 time per day for 10 days). The second group (basic group, B1) consisted of 25 NASH patients with class I obesity and COPD 2-3 D, in addition to the same basic COPD therapy, they received Antral (Farmak, Ukraine) 200 mg, 3 times per day for 60 days as a hepatoprotection. The third group (basic group, B2) included 28 NASH patients with class I obesity and COPD 2-3 D, except the same basic COPD treatment, they received Antral (Farmak, Ukraine) 200 mg, 3 times per day as a hepatoprotection, and Phytostatin (Polyconazole) (OmniFarma LLC, Ukraine) 20 mg after dinner for 30 days.
Research results. In NASH patients against the background of obesity and COPD, a significant intensity of oxidative stress has been established with an increase in the blood of intermediate and final products of lipid peroxidation content (in 1.7–2.2 times, p < 0.05) against the background of a significant deficit in the restored glutathione in the blood (in 1.6 times, p < 0.05), which was accompanied by a compensatory voltage of catalase activity (increases in 1.7 times, p < 0.05).
Conclusion. The combined prescription of Antral for 30 days led to a significant correction of oxidative-antioxidant homeostasis in NASH patients against the background of obesity and COPD with a probable decrease of malonic aldehyde, isolated double bonds, conjugated dienes (p < 0.05), a probable increase the reduced glutathione content in red blood cells (p < 0.05).
